Compare MGTX & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGTX | ARDX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2018 | 2014 |
| Metric | MGTX | ARDX |
|---|---|---|
| Price | $11.77 | $5.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $24.57 | $15.14 |
| AVG Volume (30 Days) | 817.3K | ★ 3.4M |
| Earning Date | 05-12-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $81,391,000.00 | $2,607,000.00 |
| Revenue This Year | $141.38 | $37.75 |
| Revenue Next Year | N/A | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 144.57 | N/A |
| 52 Week Low | $6.62 | $4.08 |
| 52 Week High | $15.35 | $8.40 |
| Indicator | MGTX | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 38.60 |
| Support Level | $8.84 | $4.95 |
| Resistance Level | $15.35 | $5.34 |
| Average True Range (ATR) | 0.67 | 0.17 |
| MACD | -0.20 | 0.01 |
| Stochastic Oscillator | 20.85 | 20.74 |
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.